ZEVRA THERAPEUTICS, INC.

Annual Trend FY 2016 FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025
Total Revenue $0 $0 $0 $12.8m $13.3m $28.6m $10.5m $27.5m $23.6m $106.5m
Revenue from Contract with Customer, Including Assessed Tax $0 $0 $0 $12.8m $13.3m $28.6m $10.5m $27.5m $23.6m $106.5m
Revenue, net $0 $0 $0 $12.8m $13.3m $28.6m $10.5m $27.5m $23.6m $106.5m
Cost of Revenue $10.0m $11.0m $12.2m $343k $2.9m $7.4m $16.5m
Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization $7.4m $16.5m
Research and development $20.5m $20.6m $41.8m $19.4m $8.8m $10.2m $19.6m $39.8m $42.1m $12.7m
Selling, general and administrative $15.0m $34.3m $54.9m $77.6m
Operating Expenses $33.4m $55.9m
Total operating expenses $37.5m $33.4m $55.9m $33.2m $18.9m $20.9m $53.0m $77.1m $97.0m $90.4m
Operating Income (Loss) ($37.5m) ($33.4m) ($55.9m) ($20.3m) ($5.6m) $7.7m ($42.5m) ($49.6m) ($87.0m) ($62.9m)
Additional Financial Items
Amortization of Intangible Assets $800k $6.2m $3.9m
Foreign Currency Transaction Gain (Loss), before Tax $91k $198k ($219k) ($1.5m)
Goodwill, Impairment Loss $0 $0 $0
Income (Loss) from Continuing Operations before Income Taxes, Domestic $27.1m
Interest and Other Income $365k $420k $309k
Preferred Stock Dividends and Other Adjustments $54.3m $0
Preferred Stock Dividends, Income Statement Impact $54.3m $0 $0
Intangible asset amortization $772k $6.2m $3.9m
Impairment of intangible assets $0 $58.7m
Loss from operations ($37.5m) ($33.4m) ($55.9m) ($20.3m) ($5.6m) $7.7m ($42.5m) ($49.6m) ($87.0m) ($62.9m)
Gain on sale of PRV $0 $148.3m
Fair value adjustment related to warrant and CVR liability ($98k) $2.1m $2.2m
Fair value adjustment related to investments ($13k) ($577k) $613k ($18k) $149k
Interest and other income, net $353k $365k $420k $309k $89k $248k $760k $4.5m $2.2m $6.9m
Income (loss) before income taxes ($16.5m) ($43.4m) ($56.6m) ($24.5m) ($12.8m) ($8.5m) ($42.3m) ($46.0m) ($90.1m) $86.7m
Basic (in shares) $4.0m $29.8m $34.5m $35.5m $46.3m $55.3m
Diluted (in shares) $4.0m $29.8m $46.3m $57.3m
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest ($16.5m) ($43.4m) ($56.6m) ($24.5m) ($12.8m) ($8.5m) ($42.3m) ($46.0m) ($90.1m) $86.7m
Net Income (Loss) Attributable to Parent ($16.5m) ($43.4m) ($56.5m) ($24.5m) ($12.8m) ($8.6m) ($41.5m) ($46.0m) ($105.5m) $83.2m
Net Income (Loss) Available to Common Stockholders, Basic ($16.5m) ($43.4m) ($56.5m) ($24.5m) ($12.8m) ($62.9m) ($41.5m) ($46.0m) ($105.5m) $77.6m
Earnings Per Share, Basic ($3.21) ($2.11) ($1.20) ($1.30) ($2.28) $1.40
Earnings Per Share, Diluted ($1.13) ($2.96) ($3.15) ($0.83) ($3.21) ($2.11) ($2.28) $1.35
Weighted Average Number of Shares Outstanding, Basic $4.0m 29.8m 34.5m 35.5m 46.3m 55.3m
Weighted Average Number of Shares Outstanding, Diluted 29.8m 57.3m
Research and Development Expense $20.5m $20.6m $41.8m $19.4m $8.8m $10.2m $19.6m $39.8m $42.1m $12.7m
General and Administrative Expense $12.8m $12.5m $10.8m $7.9m $8.7m $15.3m
Selling, General and Administrative Expense $34.3m $54.9m $77.6m
Costs and Expenses $37.5m $33.4m $55.9m $33.2m $18.9m $20.9m $53.0m $77.1m $97.0m $90.4m
Cost of product revenue (excluding $X and $X in intangible asset amortization for the years ended XXX XX, 20XX, and 20XX, respectively, shown separately below) $2.2m $7.4m $16.5m
Interest Expense (non-operating) $7.4m $8.0m
Interest Expense $5.8m $5.5m $4.9m $4.8m $226k $335k $1.5m ($7.4m) ($8.0m)
Current Income Tax Expense (Benefit) $13.3m
Income tax expense $15k $43k $126k $22k $34k ($34k) $786k $0 ($15.4m) ($3.4m)
Total other income (expense) $21.0m ($10.1m) ($689k) ($4.2m) ($7.2m) ($16.2m) $176k $3.6m ($3.1m) $149.6m
Income Tax Expense (Benefit) ($43k) ($126k) ($22k) ($34k) $34k ($786k) $0 $15.4m $3.4m